Skip to content
MARKETS / NASDAQ / IMNN
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Imunon, Inc. IMNN

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$-14.5M
$-14.2M
In brief

What this company does

The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase II clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). Imunon's technology platform is optimized for the delivery of DNA and mRNA therapeutics via synthetic non-viral carriers and is capable of providing cell transfection for double-stranded DNA plasmids and large therapeutic RNA segments such as mRNA.

Written from the business description in Imunon, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2022 · Revenue 0.5 · Net income -35.9
-20M201020122014201620182020202220242025
Compound annual growth
+0.0%
+0.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +0.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2022 · Operating -4984.3% · Net -7179.6%
-2000%-4000%-6000%201020122014201620182020202220242025
ROE
FY2025 · ROE -256.4%
-100%-200%201020122014201620182020202220242025

Each USD of equity lost 256 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -14.2
-8M-16M201020122014201620182020202220242025

Total assetsUSD 12.3M
EquityUSD 7.1M
CashUSD 8.8M
Current ratio2.32×

Equity funds 57% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B···0.00.00.00.00.00.0·······
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B··−0.0−0.0−0.0−0.0−0.0−0.0······0.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−6.83−16.94−2.16−5.03−3.83−10.08−0.77−0.68−2.72−11.89−1.03−1.38−0.95−3.44−5.00−1.52
Dividend / sh $················
Payout %················
ROE %−256.4−211.2−91.4−84.3−55.8−129.5−95.2−50.0−122.1−162.7−84.4−79.2−37.9−139.3−214.8·
Shares out B0.000.000.010.010.010.000.020.020.020.000.020.020.010.010.030.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 64 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 12 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image